HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Christensen, M. L. Articles by Fuseau, E. Search for Related Content PubMed PubMed Citation Articles by Christensen, M. L. Articles by Fuseau, E.

Pharmacokinetics of Sumatriptan Nasal Spray in Adolescents

From the Departments of Pharmacy and Pediatrics, Pediatric Pharmacology Research Unit, Center for Pediatric Pharmacokinetics and Therapeutics, University of Tennessee Health Science Center, Memphis, Tennessee (Dr. Christensen, Dr. Mottern); Pediatric Neurology, Inc., South Bend, Indiana (Dr. Jabbour); LeBonheur Children's Medical Center, Memphis, Tennessee (Dr. Christensen, Dr. Mottern, Dr. Jabbour); and EMF Consulting, Aix-en-Provence, France (Dr. Fuseau).

Sumatriptan is a potent and selective vascular 5-HT₁ receptor agonist effective for the treatment of migraine. In adults, intranasal sumatriptan is well absorbed and tolerated. The authors evaluated the pharmacokinetics and tolerability of a single dose of 20 mg intranasal sumatriptan in healthy adolescent migraineurs ages 12 to 17 years, administered outside of migraine attack. Serum sumatriptan levels were measured by high-performance liquid chromatography (HPLC) with electrochemical detection in serial samples collected over 8 hours. Physical exam, vital signs, clinical laboratory tests, and electrocardiogram measurements were monitored to assess safety and tolerability. A total of 16 subjects (10 males and 6 females) had pharmacokinetic data that could be analyzed, 2 withdrew from the study 30 and 60 minutes after dosing following the loss of venous access for blood sampling, and a bioanalysis failure resulted in loss of data from 3 subjects. Noncompartmental pharmacokinetic parameters (geometric mean and 95% confidence interval) for the remaining 16 subjects were as follows: C_max was 13.9 (11.0, 17.6) ng/mL, AUC was 57.3 (47.6, 69.0) ng/mL•h, and t_1/2 was 2.0 (1.8, 2.3) hours. Population pharmacokinetic analysis for all subjects (n = 21) showed that clearance and volume of distribution increase slightly with age and body size, but the changes were minimal and would not warrant dose adjustment: CL/F was 316 L (coefficient of variance [CV] = 25%) and Vd/F was 1070 L (CV = 46%). Sumatriptan was well tolerated with only minor adverse events reported, which all resolved spontaneously. The pharmacokinetic parameters in these adolescent subjects were similar to those previously reported in adults, suggesting that adolescents should be dosed similar to adults.

Key Words: Migraine • sumatriptan • nasal spray • pharmacokinetics • pharmacodynamics • adolescents

Address for reprints: Michael L. Christensen, PharmD, University of Tennessee Health Science Center, LeBonheur Children's Medical Center, 777 Washington Avenue, Room P420, Memphis, TN 38105.

This article has been cited by other articles:

				A. H. Elkind, A. Wade, and G. Ishkanian Pharmacokinetics of Frovatriptan in Adolescent Migraineurs J. Clin. Pharmacol., October 1, 2004; 44(10): 1158 - 1165. [Abstract] [Full Text] [PDF]

				M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau Pharmacokinetics of Sumatriptan Nasal Spray in Children J. Clin. Pharmacol., April 1, 2004; 44(4): 359 - 367. [Abstract] [Full Text] [PDF]